View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPLx Pharma Winddown 将来の成長Future 基準チェック /06現在、 PLx Pharma Winddownの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.すべての更新を表示Recent updatesお知らせ • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.お知らせ • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.お知らせ • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.Seeking Alpha • Aug 12PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48MPLx Pharma press release (NASDAQ:PLXP): Q2 Non-GAAP EPS of -$0.52 misses by $0.02. Revenue of $0.48M. Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.分析記事 • May 10Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.Recent Insider Transactions • Mar 24Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 21Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 18Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.分析記事 • Nov 03Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is ReasonableDespite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...分析記事 • Sep 23We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...Seeking Alpha • Sep 17PLx Pharma: First Commercial Launch Makes It AttractivePLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.Recent Insider Transactions • Jun 16Executive Chairman recently bought US$100k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly US$12.48 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of US$300k worth in shares.分析記事 • Jun 15PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, PLx Pharma...Major Estimate Revision • May 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.82 to -US$1.29 per share. Revenue forecast of US$7.27m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$16.00 unchanged from last update. Share price rose 2.9% to US$11.39 over the past week.Major Estimate Revision • Mar 19Consensus revenue estimates increase to US$6.80mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$1.40m to US$6.80m. Forecast losses expected to reduce from -US$1.12 to -US$1.03 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$12.00 unchanged from last update. Share price rose 27% to US$10.07 over the past week.Analyst Estimate Surprise Post Earnings • Mar 14Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 100% compared to a 22% growth forecast for the Pharmaceuticals industry in the US.Recent Insider Transactions • Mar 10Executive Chairman recently bought US$200k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly US$8.00 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.分析記事 • Mar 05Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Is New 90 Day High Low • Feb 10New 90-day high: US$6.89The company is up 99% from its price of US$3.47 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: US$6.50The company is up 103% from its price of US$3.21 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 14Earnings miss expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 1,828%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US.Is New 90 Day High Low • Nov 14New 90-day high: US$4.31The company is up 29% from its price of US$3.35 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PLx Pharma Winddown は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:PLXP.Q - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20225-28-59-59N/A6/30/202211-41-57-57N/A3/31/202210-48-45-45N/A12/31/20218-49-32-32N/A9/30/20217-61-21-21N/A6/30/20210-43-16-15N/A3/31/20210-30-13-13N/A12/31/20200-17-12-12N/A9/30/20200-11-14-13N/A6/30/20200-6-14-13N/A3/31/20200-10-13-13N/A12/31/20191-34-13-13N/A9/30/20191-29-11-11N/A6/30/20191-34-10-10N/A3/31/20191-28-9-9N/A12/31/201811-10-9N/A9/30/20181-10-14-13N/A6/30/20181-10-14-13N/A3/31/20181-9-16-15N/A12/31/20171-15-14-13N/A9/30/20170-9-8-8N/A6/30/20170-6-7-7N/A3/31/20170-5-3-3N/A12/31/20160-5-2-2N/A9/30/20160-4-2-2N/A6/30/20160-5N/A-2N/A3/31/20160-4N/A-1N/A12/31/20150-4N/A-1N/A9/30/20150-4N/A-2N/A6/30/20150-3N/A-3N/A3/31/20150-4N/A-4N/A12/31/20140-5N/A-5N/A12/31/20131-9N/A-8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PLXP.Qの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PLXP.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PLXP.Qの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PLXP.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PLXP.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PLXP.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/04 21:35終値2023/09/29 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PLx Pharma Winddown Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Kenneth TrbovichBrean Capital Historical (Janney Montgomery)Hamed KhorsandBWS Financial Inc.Jason ButlerCitizens JMP Securities, LLC3 その他のアナリストを表示
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.
Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.
Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.
Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.
お知らせ • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.
お知らせ • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.
お知らせ • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.
Seeking Alpha • Aug 12PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48MPLx Pharma press release (NASDAQ:PLXP): Q2 Non-GAAP EPS of -$0.52 misses by $0.02. Revenue of $0.48M. Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week.
分析記事 • May 10Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Apr 27Price target decreased to US$16.33Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year.
Recent Insider Transactions • Mar 24Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 21Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 18Key Executive recently bought US$50k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
分析記事 • Nov 03Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is ReasonableDespite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...
分析記事 • Sep 23We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...
Seeking Alpha • Sep 17PLx Pharma: First Commercial Launch Makes It AttractivePLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.
Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week.
Major Estimate Revision • Jul 21Consensus revenue estimates fall to US$5.73mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week.
Price Target Changed • Jul 21Price target increased to US$21.50Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year.
Recent Insider Transactions • Jun 16Executive Chairman recently bought US$100k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly US$12.48 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of US$300k worth in shares.
分析記事 • Jun 15PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, PLx Pharma...
Major Estimate Revision • May 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.82 to -US$1.29 per share. Revenue forecast of US$7.27m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$16.00 unchanged from last update. Share price rose 2.9% to US$11.39 over the past week.
Major Estimate Revision • Mar 19Consensus revenue estimates increase to US$6.80mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$1.40m to US$6.80m. Forecast losses expected to reduce from -US$1.12 to -US$1.03 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$12.00 unchanged from last update. Share price rose 27% to US$10.07 over the past week.
Analyst Estimate Surprise Post Earnings • Mar 14Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 100% compared to a 22% growth forecast for the Pharmaceuticals industry in the US.
Recent Insider Transactions • Mar 10Executive Chairman recently bought US$200k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly US$8.00 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
分析記事 • Mar 05Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Is New 90 Day High Low • Feb 10New 90-day high: US$6.89The company is up 99% from its price of US$3.47 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: US$6.50The company is up 103% from its price of US$3.21 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 14Earnings miss expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 1,828%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US.
Is New 90 Day High Low • Nov 14New 90-day high: US$4.31The company is up 29% from its price of US$3.35 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.